Germline POT1 variants can predispose to myeloid and lymphoid neoplasms

Leukemia. 2022 Jan;36(1):283-287. doi: 10.1038/s41375-021-01335-w. Epub 2021 Jun 30.

Tristan L Lim¹, David B Lieberman², Adam R Davis², Alison W Loren^{3

4}, Ryan Hausler³, Ashkan Bigdeli², Yimei Li⁵, Jacquelyn Powers^{3

4}, Anna Raper⁶, Regeneron Genetics Center⁷, Shannon A Carty⁸, Katherine L Nathanson^{4

6}, Adam Bagg², Elizabeth O Hexner^{3

4}, Kara N Maxwell^{3

4}, Jennifer J D Morrissette², Daria V Babushok^{9

10

11}

¹ Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
³ Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
⁴ Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁵ Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
⁶ Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁷ Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
⁸ Division of Hematology-Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
⁹ Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Daria.Babushok@pennmedicine.upenn.edu.
¹⁰ Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Daria.Babushok@pennmedicine.upenn.edu.
¹¹ Comprehensive Bone Marrow Failure Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Daria.Babushok@pennmedicine.upenn.edu.

No abstract available

Publication types